First Time Loading...

Amphastar Pharmaceuticals Inc
NASDAQ:AMPH

Watchlist Manager
Amphastar Pharmaceuticals Inc Logo
Amphastar Pharmaceuticals Inc
NASDAQ:AMPH
Watchlist
Price: 43.91 USD 0.9% Market Closed
Updated: Mar 29, 2024

Intrinsic Value

Amphastar Pharmaceuticals, Inc. engages in the development, manufacture, market, and sale of technically challenging and proprietary injectable, inhalation, and intranasal products. [ Read More ]

The intrinsic value of one AMPH stock under the Base Case scenario is 61.57 USD. Compared to the current market price of 43.91 USD, Amphastar Pharmaceuticals Inc is Undervalued by 29%.

Key Points:
AMPH Intrinsic Value
Base Case
61.57 USD
Undervaluation 29%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Amphastar Pharmaceuticals Inc

Backtest AMPH Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling AMPH stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Financials

Balance Sheet Decomposition
Amphastar Pharmaceuticals Inc

Current Assets 489.6m
Cash & Short-Term Investments 256.8m
Receivables 115.5m
Other Current Assets 117.3m
Non-Current Assets 1B
Long-Term Investments 15.2m
PP&E 315.6m
Intangibles 613.3m
Other Non-Current Assets 79.2m
Current Liabilities 225.4m
Accounts Payable 25.4m
Accrued Liabilities 197.9m
Other Current Liabilities 2m
Non-Current Liabilities 648.1m
Long-Term Debt 589.6m
Other Non-Current Liabilities 58.5m
Efficiency

Earnings Waterfall
Amphastar Pharmaceuticals Inc

Revenue
644.4m USD
Cost of Revenue
-290.6m USD
Gross Profit
353.8m USD
Operating Expenses
-154.1m USD
Operating Income
199.7m USD
Other Expenses
-62.1m USD
Net Income
137.5m USD

Free Cash Flow Analysis
Amphastar Pharmaceuticals Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

AMPH Profitability Score
Profitability Due Diligence

Amphastar Pharmaceuticals Inc's profitability score is 66/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Positive Free Cash Flow
ROE is Increasing
Exceptional 3-Years Revenue Growth
66/100
Profitability
Score

Amphastar Pharmaceuticals Inc's profitability score is 66/100. The higher the profitability score, the more profitable the company is.

AMPH Solvency Score
Solvency Due Diligence

Amphastar Pharmaceuticals Inc's solvency score is 58/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
High Interest Coverage
58/100
Solvency
Score

Amphastar Pharmaceuticals Inc's solvency score is 58/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

AMPH Price Targets Summary
Amphastar Pharmaceuticals Inc

Wall Street analysts forecast AMPH stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for AMPH is 67.32 USD with a low forecast of 61.61 USD and a high forecast of 74.55 USD.

Lowest
Price Target
61.61 USD
40% Upside
Average
Price Target
67.32 USD
53% Upside
Highest
Price Target
74.55 USD
70% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

AMPH Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

AMPH Price
Amphastar Pharmaceuticals Inc

1M 1M
-6%
6M 6M
-5%
1Y 1Y
+17%
3Y 3Y
+142%
5Y 5Y
+115%
10Y 10Y
+402%
Annual Price Range
43.91
52w Low
35.77
52w High
65
Price Metrics
Average Annual Return 8.9%
Standard Deviation of Annual Returns 12.03%
Max Drawdown -45%
Shares Statistics
Market Capitalization 2.1B USD
Shares Outstanding 48 095 900
Percentage of Shares Shorted 12.22%

AMPH Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Amphastar Pharmaceuticals Inc Logo
Amphastar Pharmaceuticals Inc

Country

United States of America

Industry

Pharmaceuticals

Market Cap

2.1B USD

Dividend Yield

0%

Description

Amphastar Pharmaceuticals, Inc. engages in the development, manufacture, market, and sale of technically challenging and proprietary injectable, inhalation, and intranasal products. The company is headquartered in Rancho Cucamonga, California and currently employs 1,761 full-time employees. The company went IPO on 2014-06-25. The firm is primarily focused on developing, manufacturing, marketing and selling generic and injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient (API) products. Its segments include Finished pharmaceutical products and API products. The Finished pharmaceutical products segment manufactures, markets and distributes Primatene Mist, glucagon, enoxaparin, naloxone, phytonadione, lidocaine, epinephrine, various critical and non-critical care drugs, as well as certain contract manufacturing. The API segment manufactures and distributes recombinant human insulin API and porcine insulin API for external customers and internal product development. Primatene Mist is an epinephrine inhalation product, which is indicated for the temporary relief of mild symptoms of intermittent asthma. Glucagon for injection emergency kit is indicated for the treatment of severe hypoglycemia.

Contact

CALIFORNIA
Rancho Cucamonga
11570 6th St
+19099809484.0
http://www.amphastar.com

IPO

2014-06-25

Employees

1 761

Officers

Chairman of the Board, Chief Scientist & COO
Dr. Ziping Luo Ph.D.
Co-Founder, President, CEO, Chief Scientific Officer & Director
Dr. Yongfeng Zhang Ph.D.
CFO, Executive VP of Finance, Treasurer & Director
Mr. William J. Peters M.B.A.
Executive VP of Sales, Marketing & Corporate Administration Center, Corporate Secretary and Director
Mr. Jacob Liawatidewi M.B.A.
Senior Executive Vice President of Production
Mr. Rong Zhou M.S.
Vice President of Human Resources & Corporate Communication
Dan Dischner M.B.A.
Show More
Senior VP of Regulatory Affairs & Clinical Operations
Tony Marrs M.B.A., M.P.H.
Show Less

See Also

Discover More
What is the Intrinsic Value of one AMPH stock?

The intrinsic value of one AMPH stock under the Base Case scenario is 61.57 USD.

Is AMPH stock undervalued or overvalued?

Compared to the current market price of 43.91 USD, Amphastar Pharmaceuticals Inc is Undervalued by 29%.